BACKGROUND: In perioperative management of hepatic resection for hepatocellular carcinoma, excessive blood loss and blood transfusion greatly influence postoperative complications and prognosis of the patients. We evaluated the influence of blood products use on postoperative recurrence and prognosis of patients with hepatocellular carcinoma. METHODS: The subjects were 66 patients who underwent elective hepatic resection for hepatocellular carcinoma without concomitant microwave or radiofrequency ablation therapy nor other malignancies between January 2001 and June 2006. We retrospectively investigated the influence of the use of blood products including red cell concentration and fresh frozen plasma on recurrence of hepatocellular carcinoma and overall survival. RESULTS: In multivariate analysis, the dose of blood products transfusion was a significant predictor of disease-free and overall survival. Both disease-free and overall survival rates of those who were given blood products were significantly worse than those who did not receive. On the other hand, in univariate analysis of disease-free and overall survival after hepatic resection and clinical variables, the amount of blood loss was not a significant predictor of recurrence or death. CONCLUSION: Transfusion of blood products is associated with increased recurrence rate and worse survival after elective hepatic resection for patients with hepatocellular carcinoma.
BACKGROUND: In perioperative management of hepatic resection for hepatocellular carcinoma, excessive blood loss and blood transfusion greatly influence postoperative complications and prognosis of the patients. We evaluated the influence of blood products use on postoperative recurrence and prognosis of patients with hepatocellular carcinoma. METHODS: The subjects were 66 patients who underwent elective hepatic resection for hepatocellular carcinoma without concomitant microwave or radiofrequency ablation therapy nor other malignancies between January 2001 and June 2006. We retrospectively investigated the influence of the use of blood products including red cell concentration and fresh frozen plasma on recurrence of hepatocellular carcinoma and overall survival. RESULTS: In multivariate analysis, the dose of blood products transfusion was a significant predictor of disease-free and overall survival. Both disease-free and overall survival rates of those who were given blood products were significantly worse than those who did not receive. On the other hand, in univariate analysis of disease-free and overall survival after hepatic resection and clinical variables, the amount of blood loss was not a significant predictor of recurrence or death. CONCLUSION: Transfusion of blood products is associated with increased recurrence rate and worse survival after elective hepatic resection for patients with hepatocellular carcinoma.
Authors: Monica M Dua; David J Worhunsky; Kimberly Hwa; George A Poultsides; Jeffrey A Norton; Brendan C Visser Journal: Surg Endosc Date: 2014-08-27 Impact factor: 4.584
Authors: Andrew J Page; Aslam Ejaz; Gaya Spolverato; Tiffany Zavadsky; Michael C Grant; Daniel J Galante; Elizabeth C Wick; Matthew Weiss; Martin A Makary; Christopher L Wu; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2014-12-04 Impact factor: 3.452
Authors: M Gierth; A Aziz; H M Fritsche; M Burger; W Otto; F Zeman; M T Pawlik; E Hansen; M May; S Denzinger Journal: World J Urol Date: 2014-02-08 Impact factor: 4.226
Authors: Heather J Chalfin; Steven M Frank; Zhaoyong Feng; Bruce J Trock; Charles G Drake; Alan W Partin; Elizabeth Humphreys; Paul M Ness; Byong C Jeong; Seung B Lee; Misop Han Journal: Transfusion Date: 2014-03-06 Impact factor: 3.157
Authors: Laurent Sulpice; Michel Rayar; Boris Campillo; Claire Pery; Antoine Guillaud; Bernard Meunier; Karim Boudjema Journal: World J Surg Date: 2014-04 Impact factor: 3.352